Myomectomy for Uterine Myoma .
Conditions
Interventions
carboprost Adminstration and Tourniquet Application
Tourniquet
Sponsors
Nelson Ampah
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women diagnosed with symptomatic uterine fibroids requiring surgical intervention through abdominal myomectomy. 2. Patients with multiple or large fibroids (>5 cm), as these cases typically present with increased surgical complexity and blood loss, making them ideal for evaluating haemostatic interventions. 3. Patients with normal baseline haemoglobin levels (=10 g/dL) to minimize confounding effects of pre-existing anaemia.
Exclusion criteria
Exclusion criteria: 1. Women with known bleeding disorders or coagulopathies, as these conditions independently affect perioperative blood loss. 2. Patients with prior uterine artery embolization (UAE) or previous uterine surgeries, which may alter vascularization and affect the surgical bleeding profile. 3. Women with severe anaemia (Hb < 10 g/dL) or those requiring preoperative transfusion, as their blood loss tolerance differs from the general study population. 4. Patients with contraindications to carboprost tromethamine use, such as a history of asthma or cardiovascular disease, due to the risk of adverse effects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Women who receive combined intramuscular carboprost and a tourniquet may experience a significantly smaller drop in haemoglobin levels from preoperative to postoperative measurements compared to those who receive a tourniquet alone, indicating reduced intraoperative blood loss. Alternatively, there may be no significant difference in the change in haemoglobin levels between the two groups, suggesting that carboprost does not provide additional benefit in minimizing blood loss. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The combination of intramuscular carboprost and a tourniquet may lead to a lower proportion of patients requiring blood transfusion, demonstrating its effectiveness in minimizing severe blood loss. Conversely, the need for transfusion may remain similar between both groups, which would indicate that carboprost does not significantly impact transfusion rates. 2. The combined use of intramuscular carboprost and tourniquet may contribute to a shorter surgical duration, as less time may be needed to achieve haemostasis. On the other hand, there may be no significant reduction in operative time between the two groups. | — |
Countries
Ghana
Contacts
Public ContactRansford Frempong
Obstetrician Gynecologist
Outcome results
None listed